Review
As chimeric antigen receptor (CAR) T cells have displayed an unprecedented efficacy in the treatment of CD19-positive malignances, it is believed that this cell therapy will be a milestone in the history of ma...
Experimental Hematology & Oncology 2017 6:28
Published on: 11 October 2017
Research
Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with rela...
Experimental Hematology & Oncology 2017 6:27
Published on: 3 October 2017
Research
Post-transplant lymphoproliferative disorder is a well-recognized but rare complication of hematopoietic stem cell and solid organ transplant. Due to rarity of this disease, retrospective studies from major tr...
Experimental Hematology & Oncology 2017 6:26
Published on: 29 September 2017
Case report
Prostate cancer most commonly metastasizes to bones or lymph nodes, and metastatic prostate cancer is suggestive of disseminated disease. Metastatic disease is usually not amenable to surgery.
Experimental Hematology & Oncology 2017 6:25
Published on: 15 September 2017
Review
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor ...
Experimental Hematology & Oncology 2017 6:24
Published on: 9 August 2017
Review
Macrophages are an essential component of innate immunity and play a vital role in inflammation and host defense. Based on immunological responses, the macrophages are classified into “activated” macrophage (M...
Experimental Hematology & Oncology 2017 6:23
Published on: 8 August 2017
Short report
Traditional two-dimensional (2-D) monolayer cell culture is vastly different from in vivo physiological conditions, which can lead to inaccurate or insufficient data in areas where response and efficacy within...
Experimental Hematology & Oncology 2017 6:22
Published on: 7 August 2017
Review
B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on pa...
Experimental Hematology & Oncology 2017 6:20
Published on: 14 July 2017
Case report
Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening condition caused by the binding of platelet-activating antibodies (IgG) to multimolecular platelet factor 4 (PF4)/heparin complexes because...
Experimental Hematology & Oncology 2017 6:21
Published on: 14 July 2017
Research
Nuclear PTEN plays an important role during mitosis. To understand the molecular basis by which PTEN mediates mitotic progression, we examined whether PTEN regulated the formation of mitotic checkpoint complex...
Experimental Hematology & Oncology 2017 6:19
Published on: 29 June 2017
Research
Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive p...
Experimental Hematology & Oncology 2017 6:18
Published on: 19 June 2017
Review
Cullin 4B (CUL4B) is a scaffold of the Cullin4B-Ring E3 ligase complex (CRL4B) that plays an important role in proteolysis and is implicated in tumorigenesis. Aberrant expression of CUL4B has been reported in ...
Experimental Hematology & Oncology 2017 6:17
Published on: 15 June 2017
Research
Multiple myeloma (MM) is a type of hematological malignancy with significant heterogeneity in clinical features and prognosis. Cytogenetic abnormalities are the major factors affecting patient outcomes. Studie...
Experimental Hematology & Oncology 2017 6:16
Published on: 26 May 2017
Letter to the Editor
Blockade of the programmed cell death protein 1 (PD1) pathway is clinically effective against human cancers. Although multiple types of malignancies have been shown to respond to PD1 agents, only a small perce...
Experimental Hematology & Oncology 2017 6:15
Published on: 24 May 2017
Research
Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluat...
Experimental Hematology & Oncology 2017 6:14
Published on: 18 May 2017
Case report
Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the fir...
Experimental Hematology & Oncology 2017 6:13
Published on: 3 May 2017
Review
During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wi...
Experimental Hematology & Oncology 2017 6:12
Published on: 2 May 2017
Case report
Esophageal cancer including squamous cell carcinoma (SCC) and adenocarcinoma represents 4% of all cancers in the United States. Patients with esophageal cancer frequently present with locally advanced disease,...
Experimental Hematology & Oncology 2017 6:11
Published on: 18 April 2017
Review
Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause of cancer-associated morbidity and mortality for children and adults. Developing novel and effective molecular-targeted...
Experimental Hematology & Oncology 2017 6:10
Published on: 14 April 2017
Case report
Osteolytic bone lesions and hypercalcemia without peripheral blasts B-cell acute lymphoblastic leukemia (B-ALL) is reported in children but rarely seen in adults.
Experimental Hematology & Oncology 2017 6:9
Published on: 11 April 2017
Case report
Acquired factor VIII (FVIII) deficiency, or acquired hemophilia A (AHA), is a rare autoimmune disorder involving antibody-mediated depletion of coagulation FVIII, leading to severe, life-threatening bleeding. ...
Experimental Hematology & Oncology 2017 6:8
Published on: 24 March 2017
Review
The purpose of this systematic review is to discuss recent studies and ongoing trials of nab-paclitaxel in breast cancer and to examine the potential role of nab-paclitaxel as a backbone for immuno-oncology thera...
Experimental Hematology & Oncology 2017 6:7
Published on: 22 March 2017
Case report
The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK...
Experimental Hematology & Oncology 2017 6:6
Published on: 21 March 2017
Research
Chemotherapy-induced polyneuropathy (CIPN) is a common toxicity after chemotherapy, immunomodulatory drugs or proteasome inhibitors, which is difficult to treat and may also have impact on quality of life. The...
Experimental Hematology & Oncology 2017 6:5
Published on: 7 February 2017
Case report
Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome is cau...
Experimental Hematology & Oncology 2017 6:4
Published on: 13 January 2017
